Idorsia Japan confirms daridorexant dose response in Japanese patients with i.. Idorsia announces financial results for the first half 2020. Last update: 08.10.2020 . Idorsia Ltd is part of the following indices: SPI, SPIEX, SXSLI, SXI Life Sciences, and SXI Bio+Medtech. On July 13, 2018 the Group privately placed 11,912,000 new registered shares of CHF 0.05 par value from existing authorized capital at CHF 25.62 per new share receiving gross proceeds of CHF 305 million through an accelerated bookbuilding. Idorsia Japan confirms daridorexant dose response in Japanese patients with i.. Idorsia announces financial results for the first half 2020. Idorsia is more than a startup: we have an experienced team and a full pipeline. On May 22, 2020 the Group privately placed 11 million new registered shares of CHF 0.05 par value from existing authorized share capital at CHF 30 per new share receiving gross proceeds of CHF 330 million, by way of an accelerated book-building process. View all. Invitation to Idorsia's half year financial results 2020 webcast and conferen.. Idorsia establishes US commercial operations and leadership team. Located near Basel, Switzerland – a bona fide European biotech hub – Idorsia is specialized in the discovery and development of small molecules to provide innovative therapeutic possibilities. This website is subject to the terms and conditions outlined in the legal and privacy statement. Further stock information; Contact. Furthermore, shares issued through the conversion of the first tranche of the convertible loan provided by Cilag Holding AG, an indirect subsidiary of Johnson & Johnson (CHF 135.4 million converting into 11,793,220 Idorsia shares (“Authorized Shares”) were listed on June 20, 2017. ), Johnson & Johnson's Cilag to sell up to 11.8 million Idorsia shares. Idorsia announces capital increase to prepare for the launch of daridorexant and further fund its diversified pipeline. You will get the news sent to you. The Bonds mature on July 17, 2024 and are convertible into 5.9 million registered shares of the Group. Find the latest status of our clinical development pipeline, including information … Investors wishing to become a shareholder in Idorsia should contact their local bank with the following information: Bank staff will then be able to use this information to execute the transaction. Idorsia Pharmaceuticals Ltd. Hegenheimermattweg 91. Stock analysis for Idorsia Ltd (IDIA:SIX Swiss Ex) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Investors wishing to register their shares are kindly asked to contact their prime custodian (e.g. Idorsia has mandated areg.ch to administer its Share Register. On July 13, 2018 the Group privately placed 11,912,000 new registered shares of CHF 0.05 par value from existing authorized capital at CHF 25.62 per new share receiving gross proceeds of CHF 305 million through an accelerated bookbuilding. After completing the form, your custodian will send it to areg.ch who will then take care of the registration. Idorsia announces positive results in the second Phase 3 study of daridorexan.. Événements importants des semaines 42 et 43 du 14.10.2020 au 24.10.2020, Événements importants des semaines 42 et 43 du 13.10.2020 au 24.10.2020, Chief Financial Officer & Executive Vice President, Head-Global Clinical Development & Executive VP. Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. Legal & privacy statement|Site map|Cookie policy|Webmaster, Copyright © 2020 Idorsia Pharmaceuticals Ltd, Major Shareholder on www.six-swiss-exchange.com. Idorsia veut lever 575 millions pour préparer le lancement du daridorexant: 05:41a: Aktien Schweiz: Hoffnung auf weitere konjunkturelle Hilfen stützt: 05:31a: Bourse Zurich: le vert reste de mise à l'approche de la mi-journée: 05:16a: Idorsia veut lever 575 millions … As part of our continued efforts towards good corporate governance we encourage shareholders to exercise their voting rights at the Annual General Meeting (AGM) of Idorsia Ltd. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan... Idorsia announces capital increase to prepare for the launch of daridorexant and further fund its diversified pipeline. Idorsia offers an electronic ‘Stay informed’ service. Idorsia selects Syneos Health as commercialization partner to launch daridore.. Daridorexant Phase 3 results in insomnia presented at SLEEP 2020, Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020. Therefore, registered shares are not automatically registered in our Share Register. Idorsia announces positive results in the second Phase 3 study of daridorexan.. Idorsia successfully completes the offering of new shares thereby securing fu.. Idorsia launches an offering of new shares to fund the company's growth plan, Idorsia holds its third Annual General Meeting of Shareholders, Événements importants des semaines 42 et 43 du 15.10.2020 au 24.10.2020, Événements importants des semaines 42 et 43 du 14.10.2020 au 24.10.2020, Événements importants des semaines 42 et 43 du 13.10.2020 au 24.10.2020, Événements importants des semaines 42 et 43 du 12.10.2020 au 24.10.2020, Calendrier des semaines 42 à 45 en 2020 (CP, résultats, BNS, etc.